newsfilter
← Latest News
GlobeNewswire·

AEON Biopharma Announces Pricing of Upsized $13.75 Million Public Offering with Accompanying Milestone Warrants Providing Potential for Additional Future Funding

  • AEON Biopharma, Inc. priced an underwritten public offering to raise approximately $43.3 million in gross proceeds.
  • The offering includes 42,688,606 shares of common stock or pre-funded warrants accompanied by two-year & five-year milestone warrants.
  • The combined public offering price is $0.3221 per common stock unit, consisting of one share & two warrants.
  • Expected gross proceeds from the initial offering are $13.75 million, with an additional potential $29.6 million if all milestone warrants are exercised in cash.
  • The two-year milestone warrants expire on the second anniversary of issuance or 45 days after achieving a specified regulatory milestone for ABP-450.
  • The five-year milestone warrants expire on the fifth anniversary of issuance or 45 days after achieving a specified clinical development milestone for ABP-450.
  • The representative has a 30-day option to purchase up to 6,403,290 additional shares or warrants to cover over-allotments.
  • Proceeds are intended for working capital & general corporate purposes, including comparative analytical testing on ABP-450 to support biosimilarity to BOTOX®.
  • Lake Street Capital Markets, LLC is acting as the sole bookrunner & Laidlaw & Company (UK) Ltd. is the lead manager.
  • The offering is expected to close on or about July 15, 2026, subject to customary closing conditions.
  • A Form S-1 Registration Statement was declared effective by the SEC on July 13, 2026.
  • ABP-450 is a proposed biosimilar to BOTOX® for therapeutic indications & is the same botulinum toxin complex marketed by Evolus, Inc. as Jeuveau® for cosmetic use.